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Background-—Long-chain polyunsaturated omega-3 fatty acids (n-3 PUFA) demonstrated antiarrhythmic potential in experimental
studies. In a large multinational randomized trial (OPERA), perioperative ﬁsh oil supplementation did not reduce the risk of
postoperativeatrialﬁbrillation(PoAF)incardiacsurgerypatients.However,whetherpresupplementationhabitualplasmaphospholipid
n-3 PUFA, or achieved or change in n-3 PUFA level postsupplementation are associated with lower risk of PoAF is unknown.
Methods and Results-—In 564 subjects undergoing cardiac surgery between August 2010 and June 2012 in 28 centers across 3
countries, plasma phospholipid levels of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid
(DHA) were measured at enrollment and again on the morning of cardiac surgery following ﬁsh oil or placebo supplementation
(10 g over 3 to 5 days, or 8 g over 2 days). The primary endpoint was incident PoAF lasting ≥30 seconds, centrally adjudicated,
and conﬁrmed by rhythm strip or ECG. Secondary endpoints included sustained (≥1 hour), symptomatic, or treated PoAF; the time
to ﬁrst PoAF; and the number of PoAF episodes per patient. PoAF outcomes were assessed until hospital discharge or
postoperative day 10, whichever occurred ﬁrst. Relative to the baseline, ﬁsh oil supplementation increased phospholipid
concentrations of EPA (+142%), DPA (+13%), and DHA (+22%) (P<0.001 each). Substantial interindividual variability was observed
for change in total n-3 PUFA (range=0.7% to 7.5% after 5 days of supplementation). Neither individual nor total circulating n-3
PUFA levels at enrollment, morning of surgery, or change between these time points were associated with risk of PoAF. The
multivariable-adjusted OR (95% CI) across increasing quartiles of total n-3 PUFA at enrollment were 1.0, 1.06 (0.60 to 1.90), 1.35
(0.76 to 2.38), and 1.19 (0.64 to 2.20); and for changes in n-3 PUFA between enrollment and the morning of surgery were 1.0,
0.78 (0.44 to 1.39), 0.89 (0.51 to 1.55), and 1.01 (0.58 to 1.75). In stratiﬁed analysis, demographic, medication, and cardiac
parameters did not signiﬁcantly modify these associations. Findings were similar for secondary PoAF endpoints.
Conclusions-—Among patients undergoing cardiac surgery, neither higher habitual circulating n-3 PUFA levels, nor achieved levels
or changes following short-term ﬁsh oil supplementation are associated with risk of PoAF.
Clinical Trial Registration-—URL: Clinicaltrials.gov Unique identiﬁer: NCT00970489 (J Am Heart Assoc. 2013;2:e000397 doi:
10.1161/JAHA.113.000397)
Key Words: biomarker ￿ cardiac surgery ￿ omega-3 fatty acids ￿ postoperative atrial ﬁbrillation ￿ randomized controlled trial
P
ostoperative atrial ﬁbrillation (PoAF) is a major compli-
cation of cardiac surgery and can cause hemodynamic
disturbances, thromboembolic events, cognitive impairment,
extended hospital stay, and increased health care use and
costs.
1 Current prophylactic therapy such as perioperative
b-blockers and amiodarone partially reduce overall incidence
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ORIGINAL RESEARCHof PoAF, and postoperative anticoagulation can increase
bleeding risk.
1,2 Despite decades of improvement in medical
and surgical care, the incidence of PoAF remains largely
unchanged,
1,3 and novel preventive measures are urgently
needed.
Seafood-derived long-chain omega-3 polyunsaturated fatty
acids (n-3 PUFA) reduced susceptibility to atrial arrhythmia in
animal disease models.
4–6 Yet, in large randomized trials
including the Omega-3 Fatty Acids for Prevention of Postop-
erative Atrial Fibrillation (OPERA) trial, short-term periopera-
tive ﬁsh oil supplementation did not reduce PoAF.
7–9
However, several important questions were not addressed
by these studies. First is whether higher habitual circulating
levels of n-3 PUFA, which through long-term improvement in
CVD risk factors such as lowering blood pressure and direct
myocardial membrane effects,
10 could be associated with
lower risk of PoAF. Second, it is unknown if subjects who
achieve the highest levels of n-3 PUFA following supplemen-
tation, or who experience the greatest changes in levels,
could be at lower risk of PoAF. For instance, the achieved
level of n-3 PUFA may be most relevant given potential tissue
concentration-dependent effects of n-3 PUFA on cardiac ion
channels.
11,12
We addressed these key gaps in knowledge by investigat-
ing the association of circulating plasma phospholipid n-3
PUFA with PoAF in a subset of 564 subjects in the OPERA
trial. We assessed levels of circulating n-3 PUFA at recruit-
ment (reﬂecting habitual levels prior to supplementation),
achieved levels following supplementation on the morning of
cardiac surgery (reﬂecting incorporation into circulating
phospholipids), and the within-subject change between these
time points (reﬂecting differences in subjects’ responses to
supplementation). Use of objective n-3 PUFA biomarkers also
allowed us to separately evaluate total n-3 PUFA as well as
each individual long-chain n-3 PUFA, including eicosapenta-
enoic acid (EPA), docosapentaenoic acid (DPA), and docosa-
hexaenoic acid (DHA), which may have partly differing and
complementary biologic activities.
13
Methods
Subjects and Study Design
This investigation was performed as a prospectively designed
ancillary study of the OPERA trial, the design of which has
been reported in detail.
7,14 Brieﬂy, OPERA enrolled 1516
patients undergoing cardiac surgery in 28 medical centers in
the United States, Italy, and Argentina. Inclusion criteria
included age (≥18 years), presence of sinus rhythm on the
screening electrocardiogram (ECG) and being scheduled for
cardiac surgery on the next day or later (ie, excluding
emergent surgery). Patients were excluded if they had a
known allergy or intolerance to ﬁsh oil or olive oil (placebo),
regularly used ﬁsh oil supplements, were currently pregnant,
or had an existing or planned cardiac transplant or ventricular
assist device. The study was approved by the institutional
review boards of all participating centers and all patients
provided written informed consent.
Fish Oil Supplementation
Following enrollment, participants were block randomized to
supplementation with ﬁsh oil (465 mg EPA and 375 mg
DHA as ethyl esters per 1 g capsule; Omacor, Pronova
Biopharma) or matched placebo (olive oil), stratiﬁed by
enrolling medical center and planned valve surgery (yes/no).
The total preoperative loading dose was 10 g divided over 3
to 5 days (or 8 g divided over 2 days), including on the
morning of surgery. The loading time frame was designed to
be ﬂexible to maximize enrollment of all possible patients; for
each patient, the dose was divided over the maximum
number of days possible, based on the date of enrollment
and the date of planned surgery. After cardiac surgery,
patients continued to receive 2 g/day until hospital dis-
charge or postoperative day 10, whichever occurred ﬁrst, at
which time administrative censoring occurred for follow-up of
PoAF.
Fatty Acid Analysis
In 17 study centers that agreed to participate in this
ancillary study, fasting blood was collected from subjects
using standardized kits and techniques, including at enroll-
ment and on the morning of cardiac surgery. EDTA
anticoagulated plasma samples were stored at 70°Ca t
each study center and then shipped on dry ice to a central
sample repository for long-term storage at 80°C. Following
completion of the trial, plasma phospholipid n-3 PUFA were
measured as percent of total phospholipid fatty acids by the
Fred Hutchinson Cancer Research Institute (Seattle, WA).
Plasma total lipids were extracted,
15 and phospholipids
isolated by thin-layer chromatography. Fatty acid methyl
esters were subsequently prepared by direct transesteri-
ﬁcation according to Lepage and Roy,
16 and analyzed by
gas chromatography (Agilent 5890 gas chromatograph
ﬂame ionization detector, Agilent Technologies; fused silica
capillary column SP-2560 [100 m90.25 mm; 0.2 lm], Supe-
lco; initial oven temperature 160°C for 16 minutes, ramp
3°C/min to 240°C, hold, 15 minutes). Interassay coefﬁcients
of variation were <3% for EPA, DPA, and DHA. A total of 564
and 550 subjects had available samples for n-3 PUFA
measurement at recruitment and on the morning of cardiac
surgery, respectively; and 523 had available samples at both
time points.
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Standardized data were collected on other risk factors for
PoAF including demographics, anthropometric parameters,
lifestyle habits, cardiovascular risk factors, medical and
surgical history, major comorbidities, outpatient and inpatient
medications, laboratory measures, and echocardiographic
parameters including left ventricular (LV) ejection fraction
and left atrial (LA) diameter. Details of the surgical procedure
and daily follow-up and discharge information were also
recorded. Information on usual habitual ﬁsh intake at
enrollment was obtained using validated semi-quantitative
food frequency questionnaires in US and Italian patients
17,18;
dietary data was not collected for subjects in Argentina.
Outcomes
Suspected episodes of PoAF were documented, including
duration, clinical information, and conﬁrmatory rhythm strip or
12-lead ECG, and reviewed by a centralized events committee
of cardiac eletrophysiologists. The primary endpoint was the
occurrence of PoAF of at least 30 seconds duration. We also
ascertained PoAF that was sustained (≥1 hour), symptomatic,
or treated with pharmacological or electrical cardioversion;
the time to ﬁrst PoAF, and the number of PoAF episodes per
patient. Outcomes were assessed until hospital discharge or
postoperative day 10, whichever occurred ﬁrst.
Statistical Analysis
We evaluated EPA, DPA, and DHA individually, and also their
sum (total long-chain n-3 PUFA). Associations of n-3 PUFA
with demographic and medical variables were assessed by
linear regressions or Pearson chi-square tests. The treatment
effect of ﬁsh oil supplementation on circulating n-3 PUFA
concentrations on the morning of surgery was investigated
using linear regression, adjusting for n-3 PUFA levels at
enrollment. The interindividual variability for change in levels
of n-3 PUFA was expressed as the coefﬁcient of variation
(CV, %), calculated as (SDn-3 PUFA/meann-3 PUFA)9100. The n-3
PUFA concentrations were evaluated in quartiles as indicator
variables, and their associations with incident PoAF were
investigated using multivariable-adjusted logistic regression.
The n-3 PUFA concentrations as a percent of total phospho-
lipid fatty acids analyzed were also examined as continuous
variables. Tests of linear trend were conducted by assigning to
participants the median value in each quartile and assessing
this as a single continuous variable. We also examined
possible nonlinear relationship between n-3 PUFA exposures
and risk of PoAF nonparametrically using restricted cubic
splines, after excluding participants with extreme values (<1st
or >99th percentile) to minimize the effects of outliers. Cox
proportional hazards and Poisson regression were used to
assess the association of n-3 PUFA with the secondary
endpoints of time to ﬁrst incident PoAF and the number of
PoAF episodes per patient, respectively. To minimize con-
founding, we adjusted for age, sex, country, body mass index,
prevalent hypertension, prevalent diabetes, prevalent coro-
nary heart disease, prevalent chronic renal failure, prevalent
heart failure, smoking, dyslipidemia, statin medication use, LV
ejection fraction, LA diameter, and logistic Euroscore.
19 As
randomized assignment to ﬁsh oil supplementation did not
alter risk of PoAF in OPERA,
7 we did not adjust for treatment
group assignment in the primary analysis. In sensitivity
analysis, additional adjustment for treatment assignment did
not materially alter the observed associations. We did not
adjust for dietary covariates. Missing covariates (<3%) were
imputed by best-subset regression using demographic/risk
variables. For LA diameter (32% missing), we used a missing
indicator category. Results were similar excluding those with
missing covariate values.
Effect modiﬁcation were evaluated in stratiﬁed analyses for
several subgroups including age (<median, ≥median), sex,
country, perioperative beta-blocker and statin use, preoper-
ative LA diameter (<median, ≥median), and preoperative LV
ejection fraction (<median, ≥median). For each subgroup,
fatty acids were assessed in stratum-speciﬁc quartiles as
indicator variables. The signiﬁcance of potential effect
modiﬁcation was tested using the Wald test for a multiplica-
tive interaction term between the fatty acid quartiles (eval-
uated as ordinal variables) and the stratiﬁcation variable. All P
values were 2 tailed (a=0.05), and analyses were performed
with Stata 12.1 (Stata Corp).
Results
The 564 subjects were enrolled in the United States (57.4%),
Italy (31.7%), and Argentina (10.8%), with approximately half
(51.4%) of the subjects assigned the ﬁsh oil treatment. At
baseline, DHA was the most abundant n-3 PUFA (meanSD,
3.151.1% of the total plasma phospholipid fatty acids),
compared with DPA (0.840.19%) and EPA (0.670.49%).
Demographic and medical characteristics at baseline accord-
ing to plasma phospholipid EPA, DPA, and DHA are shown in
Table 1. Subjects from Italy tended to have higher EPA and
DHA than subjects from the US or Argentina, whereas those
from the US had higher DPA than subjects from Italy or
Argentina. Self-reported ﬁsh consumption was higher in Italy
(2.21.6 servings/week) than in the US (1.12.1 servings/
week), and was also positively associated with plasma
phospholipid EPA and DHA (r=0.21 and 0.50, respectively),
but not DPA (r=0.16). Subjects with higher n-3 PUFA levels
were less likely to smoke; EPA and DHA levels were also
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characteristics demonstrated varied associations with each
n-3 PUFA. For example, EPA was associated with less renal
failure and higher ejection fraction, DHA was associated with
older age and more dyslipidemia, and DPA was unassociated
with most covariates. Baseline demographic and medical
characteristics were very similar between patients with
plasma fatty acid data included in the current analyses,
compared to those without blood samples (Table 2).
Compared with the placebo group, ﬁsh oil supplementation
increased EPA, DPA, DHA, and total n-3 PUFA levels
(Figure 1A). The proportional changes differed: in the ﬁsh oil
supplemented group, EPA increased by nearly 150%, DPA by
13%, and DHA by 21.9% (P<0.001 each compared with
placebo groups and with adjustment for baseline n-3 PUFA
concentrations). Given its higher starting concentration, DHA
remained the predominant n-3 PUFA postsupplementation.
On average, total n-3 PUFA increased by 38% in the ﬁsh oil
supplemented group (P<0.001) between enrollment and the
morning of surgery. However, substantial interindividual
variability was observed for change in n-3 PUFA (Figure 1B).
For example, in subjects who received 5 days of ﬁsh oil
loading, the median (minimum, maximum) of change in total
n-3 PUFA as percent of plasma phospholipid fatty acid was
2.4 (0.7, 7.5), with a coefﬁcient of variation of 64.3%.
Considerable interindividual variability was also observed for
changes in individual n-3 PUFA (not shown).
The primary endpoint occurred in 177 (32%) subjects.
Neither individual nor total circulating n-3 PUFA concentra-
tions at enrollment, on the morning of surgery, or the change
between these time points were associated with risk of PoAF
(Table 3). For example, the OR (95% CI) comparing the lowest
to the highest quartiles of total n-3 PUFA at recruitment were
1.0 (reference), 1.06 (0.60 to 1.90), 1.35 (0.76 to 2.38), and
1.19 (0.64 to 2.20) (P-trend=0.55). Findings were similar
when the analyses were restricted to subjects in the ﬁsh oil
treatment group, and also when n-3 PUFA levels and changes
were evaluated continuously as percent of total plasma
phospholipid fatty acids (not shown). Similar results were also
observed in analyses restricted to subjects with below median
levels of total plasma n-3 PUFA after ﬁsh oil supplementation
period (275 subjects, 75 incident PoAF cases). For example,
in these subjects the OR (95% CI) per 1% higher plasma total
n-3 PUFA on the morning of surgery was 1.31 (0.81 to 2.12).
Semiparametric restricted cubic splines analyses demon-
strated little evidence of overall or nonlinear associations of
phospholipid n-3 PUFA with risk of PoAF (Figure 2). All
ﬁndings were similar for the secondary PoAF endpoints (data
not shown). Results were similar excluding those with missing
covariate values.
In stratiﬁed analysis, the relationship between n-3 PUFA
concentrations and PoAF was similar in most key subgroups
deﬁned by demographics, medication use, or LV and LA
parameters(Table 4).Greaterbaselinetotaln-3PUFAappeared
to be associated with higher risk of PoAF in subjects not using
statins (n=247, extreme quartile OR=2.97; 95% CI, 1.02 to
8.60),butnotinsubjectsusingstatins(n=317,extremequartile
OR=0.51, 95% CI, 0.22 to 1.17); although this potential
interaction did not achieve statistical signiﬁcance (P=0.06).
Discussion
In this large study of cardiac surgery patients from the US,
Italy, and Argentina, higher circulating levels of individual and
Table 2. Baseline Characteristics for Subjects With and
Without Plasma Fatty Acid Measurement in the OPERA Trial
Characteristics
Plasma Fatty Acid Data Available
No (n=952), Excluded
From the Current
Analyses
Yes (n=564),
Included in the
Current Analyses
Age, y 64.412.3 62.612.7
Sex, % male 688 (72.3) 406 (72.0)
Planned valve surgery, % 470 (49.4) 315 (55.9)
Current smoking, % 119 (12.5) 76 (13.5)
BMI, kg/m
2 27.85.3 29.06.1
Hypertension, % 702 (73.7) 433 (76.8)
Dyslipidemia, % 580 (60.9) 357 (63.3)
Diabetes mellitus,% 226 (23.7) 167 (29.6)
Chronic obstructive
pulmonary disease, %
86 (9.0) 84 (14.9)
Chronic renal failure, % 60 (6.3) 36 (6.4)
Prior myocardial infarction,
%
239 (25.1) 127 (22.5)
Prior percutaneous coronary
intervention, %
101 (10.6) 78 (13.8)
Prior arrhythmias, % 111 (11.7) 80 (14.2)
Prior atrial fibrillation, % 66 (6.9) 48 (8.5)
Congestive heart failure, % 303 (31.8) 113 (20.0)
Ejection fraction, % 57.011.4 56.211.3
LA diameter, mm 41.97.6 42.57.8
b-blockers, % 576 (60.5) 301 (53.4)
Statins,% 546 (57.4) 317 (56.2)
ACE inhibitors, % 361 (37.9) 197 (34.9)
Aspirin, % 428 (45.0) 346 (61.4)
Logistic EuroScore, units 6.17.7 6.37.8
Values are meanSD for continuous variables and percent for categorical variables. ACE
indicates angiotensin-converting enzyme; BMI, body mass index; LA, left atrial; OPERA,
omega-3 fatty acids for prevention of postoperative atrial ﬁbrillation.
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PoAF, whether assessed at baseline, as achieved levels
following short-term supplementation, or as achieved changes
in levels. Notably, perioperative ﬁsh oil supplementation did
produce signiﬁcant increases in circulating n-3 PUFA level,
with the largest absolute increases in DHA and the largest
relative increases in EPA. These ﬁndings suggest that neither
higher habitual circulating levels of n-3 PUFA, nor achieved
levels or changes following short-term supplementation, are
associated with risk for PoAF.
PoAF share some common risk factors with non-surgical
AF, for example, age, hypertension, and congestive heart
failure.
20 These risk factors may each lead to atrial structural
remodeling, providing a substrate that predisposes to AF.
21 In
addition, PoAF appears to be promoted by surgery-related
changes including inﬂammation, oxidative stress, and
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Figure 1. A, Plasma phospholipid concentrations of individual and total n-3 PUFA in the OPERA trial. Subjects (n=523) received 1 to 5 days of
ﬁsh oil (8 to 10 g) (white bars) or placebo (black bars). n-3 PUFA are expressed as percentage of total plasma phospholipid fatty acids analyzed
and results are presented as meanSE of each group. *P<0.001 comparing the ﬁsh oil to placebo groups, with adjustment for baseline n-3 PUFA
concentrations. B, Change in plasma phospholipid total n-3 PUFA concentrations in subjects who received ﬁsh oil (n=267). Data were stratiﬁed by
the number of ﬁsh oil loading days presurgery. The top, middle, and lower lines of each box represent the 75th, median, and 25th percentile,
respectively. The lines extending above and below the box indicate the most extreme value within the 75th percentile+1.59(interquartile range)
and 25th percentile1.59(interquartile range), respectively. The coefﬁcient of variation of the change in total n-3 PUFA were 49.1%, 66.0%,
53.8%, 43.2%, and 64.3% for subjects who received 1 to 5 days of ﬁsh oil supplementation, respectively. DHA indicates docosahexaenoic acid;
DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; n-3 PUFA, n-3 polyunsaturated fatty acids; OPERA, omega-3 fatty acids for prevention
of postoperative atrial ﬁbrillation; SE, standard error.
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HTable 3. Multivariable-Adjusted Risk of Postoperative Atrial Fibrillation According to Plasma Phospholipid Long-Chain n-3 PUFAs in
the OPERA Trial*
Quartiles of Fatty Acid Levels
P Value
for Trend
† 1st 2nd 3rd 4th
Presupplementation (enrollment) concentrations
Total long-chain n-3 PUFA
% Phospholipid fatty acid 3.250.37 3.990.19 4.790.31 6.611.32 0.55
Number of cases/n 34/142 37/140 51/141 51/141
Odds ratio (95% CI) 1.0 (reference) 1.06 (0.60 to 1.90) 1.35 (0.76 to 2.38) 1.19 (0.64 to 2.20)
DHA
% Phospholipid fatty acid 1.960.30 2.640.16 3.340.24 4.650.76 0.70
Number of cases/n 33/141 40/141 54/141 46/141
Odds ratio (95% CI) 1.0 (reference) 1.11 (0.62 to 1.99) 1.41 (0.78 to 2.54) 0.89 (0.46 to 1.70)
DPA
% Phospholipid fatty acid 0.630.06 0.760.03 0.890.04 1.100.14 0.85
Number of cases/n 45/141 41/141 48/141 39/141
Odds ratio (95% CI) 1.0 (reference) 1.04 (0.61 to 1.79) 1.30 (0.75 to 2.24) 1.02 (0.58 to 1.80)
EPA
% Phospholipid fatty acid 0.310.06 0.470.04 0.630.05 1.260.66 0.20
Number of cases/n 37/141 38/142 48/140 50/141
Odds ratio (95% CI) 1.0 (reference) 1.04 (0.59 to 1.84) 1.30 (0.74 to 2.26) 1.40 (0.79 to 2.49)
Postsupplementation (morning of surgery) concentrations
Total long-chain n-3 PUFA
% Phospholipid fatty acid 3.600.47 4.840.33 6.000.33 8.031.18 0.29
Number of cases/n 33/138 45/137 48/138 51/137
Odds ratio (95% CI) 1.0 (reference) 1.36 (0.76 to 2.43) 1.51 (0.84 to 2.72) 1.43 (0.78 to 2.62)
DHA
% Phospholipid fatty acid 2.140.35 3.000.23 3.830.28 5.250.80 0.66
Number of cases/n 33/138 42/137 50/138 52/137
Odds ratio (95% CI) 1.0 (reference) 1.12 (0.62 to 2.01) 1.26 (0.69 to 2.30) 1.16 (0.59 to 2.27)
DPA
% Phospholipid fatty acid 0.680.07 0.830.04 0.960.04 1.170.12 0.23
Number of cases/n 46/139 36/137 50/137 45/137
Odds ratio (95% CI) 1.0 (reference) 0.81 (0.46 to 1.42) 1.34 (0.78 to 2.32) 1.24 (0.71 to 2.17)
EPA
% Phospholipid fatty acid 0.390.09 0.670.09 1.250.23 2.310.48 0.68
Number of cases/n 43/141 41/134 51/138 42/137
Odds ratio (95% CI) 1.0 (reference) 0.86 (0.49 to 1.50) 1.25 (0.73 to 2.14) 1.01 (0.58 to 1.75)
Change between morning of surgery and enrollment concentrations
Total long-chain n-3 PUFA
% Phospholipid fatty acid 0.260.67 0.320.14 1.050.34 2.770.89 0.69
Number of cases/n 43/131 39/131 40/131 44/130
Odds ratio (95% CI) 1.0 (reference) 0.78 (0.44 to 1.39) 0.89 (0.51 to 1.55) 1.01 (0.58 to 1.75)
Continued
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Hsympathetic activation.
20 In animal experiments and human
studies, n-3 PUFA favorably affects several physiologic
pathways including systemic and cardiac hemodynamics,
myocardial metabolic efﬁciency, and atrial ﬁbrosis.
10,22,23 In
addition, in 2 prior prospective cohort studies, circulating
levels of habitual DHA and total n-3 PUFA were inversely
associated with long-term risk of incident (new-onset) AF
among generally healthy ambulatory adults.
24,25 These prior
studies suggest that n-3 PUFA may favorably inﬂuence risk for
AF. Although habitual circulating n-3 PUFA was not associated
with PoAF in the current study, our data do not exclude the
possibility that n-3 PUFA may have beneﬁts speciﬁc to long-
term risk factors for ambulatory AF.
Some of the beneﬁcial cardiac effects of n-3 PUFA may be
dependent upon incorporation into cardiac membrane phos-
pholipids, for example related to altered membrane ﬂuidity,
membrane protein function, and gene regulation.
10 Interindi-
vidual variation in the extent of n-3 PUFA incorporation into
phospholipids following supplementation may therefore inﬂu-
ence their potential antiarrhythmic properties. Consistent
with prior studies in subjects with atherosclerosis,
26 we
observed large interindividual variability in the changes in n-3
PUFA following ﬁsh oil supplementation. However, neither
achieved nor changes in n-3 PUFA levels were associated with
PoAF. The changes in plasma phospholipid n-3 PUFA in the
current study are consistent with ﬁndings in other cardiac
surgery populations.
27,28 Yet, whereas changes in circulating
phospholipid n-3 PUFA correspond to myocardial membrane
changes following at least 1 week of ﬁsh oil supplementa-
tion,
27 the extent to which more short-term supplementation,
such as provided in OPERA, inﬂuences myocardial phospho-
lipids is unknown. For example, it is possible that achieved
changes in plasma phospholipid fatty acids are incompletely
reﬂected in myocardial membrane phospholipids after 1 to
5 days, which might limit efﬁcacy of perioperative ﬁsh oil
supplementation for inﬂuencing risk of PoAF.
We observed nonsigniﬁcant trends for the differences in
the association of n-3 PUFA with PoAF depending on age and
statin use. However, such exploratory subgroup results
require conﬁrmation in other studies and should be inter-
preted with caution, as these differences may likely be due to
chance, especially given the multiple tests conducted in these
exploratory analyses. Nevertheless, as limited prior studies
suggested n-3 PUFA supplementation on a background of
statin therapy could lead to additional beneﬁts such as
reduction in triglycerides and oxidative stress,
29,30 our results
highlight the need for future studies to assess if the
association of circulating n-3 PUFA biomarkers with PoAF
may be modiﬁed by certain demographic or clinical charac-
teristics such as statin therapy.
Our analysis has several strengths. The prospective design
reduced the likelihood of selection bias. We used a highly
accurate and reproducible assay to assess plasma phospho-
lipid n-3 PUFA that reduced error and misclassiﬁcation of
these exposures, and allowed assessment of individual n-3
PUFA. The detailed and careful adjudication of PoAF events by
Table 3. Continued
Quartiles of Fatty Acid Levels
P Value
for Trend
† 1st 2nd 3rd 4th
DHA
% Phospholipid fatty acid 0.170.36 0.180.07 0.480.11 1.170.45 0.45
Number of cases/n 39/131 35/132 43/130 49/130
Odds ratio (95% CI) 1.0 (reference) 0.83 (0.47 to 1.48) 1.06 (0.59 to 1.88) 1.15 (0.65 to 2.03)
DPA
% Phospholipid fatty acid 0.080.11 0.020.02 0.090.02 0.230.11 0.98
Number of cases/n 39/131 47/131 38/131 42/130
Odds ratio (95% CI) 1.0 (reference) 1.02 (0.58 to 1.80) 0.88 (0.50 to 1.57) 1.02 (0.58 to 1.79)
EPA
% Phospholipid fatty acid 0.210.33 0.030.04 0.530.25 1.620.47 0.93
Number of cases/n 48/131 39/131 37/131 42/130
Odds ratio (95% CI) 1.0 (reference) 1.01 (0.57 to 1.80) 0.83 (0.47 to 1.45) 1.03 (0.59 to 1.79)
CI indicates conﬁdence interval; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; LA, left atrial; n-3 PUFA, n-3 polyunsaturated fatty acids;
OPERA, omega-3 fatty acids for prevention of postoperative atrial ﬁbrillation.
*Adjusted for age (years), gender (male/female), country (Italy, US, Argentina), body mass index (kg/m
2), prevalent hypertension (yes/no), prevalent diabetes (yes/no), prevalent coronary
heart disease (yes/no), prevalent chronic renal failure (yes/no), prevalent heart failure (yes/no), smoking (never or former/current), dyslipidemia (yes/no), statin medication use (yes/no),
ejection fraction (%), LA diameter (tertiles), and logistic Euroscore (continuous).
†Linear trend was tested by assigning to participants the median value in each quartile and assessing this as a continuous variable. All ﬁndings were similar when fatty acid concentrations
were evaluated in their natural units as continuous exposures.
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Ha centralized events committee lowered the likelihood of
misclassiﬁed outcomes. We collected information on many
well-measured covariates to allow detailed adjustment to
control for confounding. OPERA subjects were recruited from
different countries with varied population characteristics (eg,
differences in habitual ﬁsh intake), which increases general-
izability.
Limitations should also be considered. Although we
adjusted for major demographic, lifestyle, and clinical risk
factors, it is possible that unmeasured or imprecisely
measured factors could have caused residual confounding.
The OPERA trial was powered to investigate the effect of
perioperative ﬁsh oil treatment on the risk of PoAF, and not
for the current nested n-3 PUFA biomarker study. Addition-
ally, although the current analysis represents by far the
largest study using objective biomarkers of n-3 PUFA in
cardiac surgery patients, these measures were only available
in a subset of OPERA subjects, reducing statistical power,
and may narrow the generalizability of our ﬁndings. However,
demographic characteristics of subjects with fatty acid data
included in the current analysis were largely similar to other
subjects in the OPERA trial, which suggests sample avail-
ability is unlikely to have substantially affected generalizabil-
ity of our results. Only preoperative plasma n-3 PUFA was
available in our study, and we were not able to examine the
potential relationship between PoAF and postoperative
changes in n-3 PUFA, which should be examined in future
studies. Our ﬁndings are applicable to cardiac surgery
patients and short-term ﬁsh oil supplementation, and ﬁndings
may differ in other populations at risk for AF or with longer-
term supplementation.
In summary, we found that baseline levels of circulating n-3
PUFA were not associated with risk of PoAF in patients
undergoing cardiac surgery. We also found considerable
interindividual variation in responses to short-term ﬁsh oil
supplementation, but that neither achieved n-3 PUFA levels
nor changes in n-3 PUFA levels were associated with PoAF.
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Figure 2. Multivariable-adjusted association of change in plasma phospholipid total long-chain n-3 PUFA with risk of postoperative atrial
ﬁbrillation, evaluated by restricted cubic splines. Adjusted for age (years), gender (male/female), country (US, Italy, Argentina), body mass index
(kg/m
2), prevalent hypertension (yes/no), prevalent diabetes (yes/no), prevalent coronary heart disease (yes/no), prevalent chronic renal failure
(yes/no), prevalent heart failure (yes/no), smoking (never or former/current), dyslipidemia (yes/no), statin medication use (yes/no), ejection
fraction (%), LA diameter (tertiles), and logistic Euroscore (continuous). The solid red line and dashed black lines represent the odds ratio and 95%
CIs, respectively, in comparison to the reference level representing the median value of the lowest quartile (12.5th percentile). The values shown
on the x-axis correspond to the 10th, 25th, 50th, 75th, and 90th percentiles for changes in total n-3 PUFA. There was little evidence of either
overall association (Wald-test P=0.70) or nonlinearity (P=0.50). CI indicates conﬁdence interval; n-3 PUFA, n-3 polyunsaturated fatty acids.
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HTable 4. Multivariable Adjusted Association of Plasma Phospholipid Total Long-Chain n-3 PUFAs With Risk of Postoperative Atrial
Fibrillation, According to Prespeciﬁed Subgroups*
Quartiles of Fatty Acid Levels (Odds Ratios)
P Value
for Trend
†
P Value
for Interaction
‡ 1st 2nd 3rd 4th
Enrollment n-3 PUFA concentrations
Country
§
Italy (n=179) 1.0 (reference) 2.25 (0.84 to 6.04) 0.96 (0.35 to 2.64) 2.32 (0.86 to 6.26) 0.16 0.61
US (n=324) 1.0 (reference) 2.46 (1.11 to 5.48) 1.71 (0.74 to 3.94) 1.92 (0.83 to 4.45) 0.36
Age, y
<64 (n=272) 1.0 (reference) 1.93 (0.73 to 5.07) 2.70 (1.02 to 7.13) 3.27 (1.15 to 9.34) 0.04 0.35
≥64 (n=292) 1.0 (reference) 0.91 (0.45 to 1.87) 0.88 (0.42 to 1.82) 0.77 (0.35 to 1.65) 0.50
Sex
Women (n=158) 1.0 (reference) 2.59 (0.74 to 9.14) 2.28 (0.66 to 7.84) 1.17 (0.31 to 4.34) 0.68 0.65
Men (n=406) 1.0 (reference) 0.95 (0.48 to 1.89) 1.32 (0.68 to 2.57) 1.31 (0.63 to 2.71) 0.34
Statins
No (n=247) 1.0 (reference) 2.14 (0.81 to 5.66) 3.02 (1.10 to 8.29) 2.97 (1.02 to 8.60) 0.10 0.06
Yes (n=317) 1.0 (reference) 0.68 (0.32 to 1.47) 0.77 (0.36 to 1.64) 0.51 (0.22 to 1.17) 0.15
b-blockers
No (n=263) 1.0 (reference) 0.98 (0.40 to 2.39) 1.33 (0.57 to 3.14) 1.75 (0.69 to 4.41) 0.16 0.13
Yes (n=301) 1.0 (reference) 0.93 (0.42 to 2.09) 1.27 (0.57 to 2.80) 0.69 (0.29 to 1.65) 0.41
Ejection fraction, %
<60 (n=270) 1.0 (reference) 1.69 (0.70 to 4.08) 2.31 (0.98 to 5.42) 1.91 (0.75 to 4.87) 0.25 0.35
≥60 (n=294) 1.0 (reference) 0.80 (0.36 to 1.78) 0.98 (0.43 to 2.24) 0.83 (0.35 to 1.94) 0.75
LA diameter, mm
<42 (n=166) 1.0 (reference) 4.87 (1.23 to 19.3) 7.02 (1.73 to 28.5) 3.30 (0.67 to 16.2) 0.63 0.24
≥42 (n=218) 1.0 (reference) 0.59 (0.23 to 1.53) 1.26 (0.50 to 3.15) 1.09 (0.41 to 2.94) 0.57
Morning of surgery n-3 PUFA concentrations
Country
§
Italy (n=176) 1.0 (reference) 0.96 (0.36 to 2.56) 1.33 (0.49 to 3.62) 1.58 (0.59 to 4.19) 0.28 0.85
US (n=319) 1.0 (reference) 0.83 (0.37 to 1.86) 1.35 (0.62 to 2.94) 1.25 (0.58 to 2.74) 0.35
Age, y
<64 (n=269) 1.0 (reference) 0.79 (0.31 to 2.0) 1.27 (0.52 to 3.07) 1.82 (0.72 to 4.61) 0.12 0.90
≥64 (n=282) 1.0 (reference) 1.93 (0.89 to 4.17) 1.26 (0.57 to 2.76) 1.45 (0.66 to 3.22) 0.70
Sex
Women (n=151) 1.0 (reference) 2.07 (0.59 to 7.32) 1.31 (0.35 to 4.95) 1.96 (0.52 to 7.33) 0.53 0.81
Men (n=399) 1.0 (reference) 1.30 (0.65 to 2.58) 1.67 (0.84 to 3.33) 1.49 (0.73 to 3.02) 0.27
Statins
No (n=232) 1.0 (reference) 1.07 (0.40 to 2.84) 2.01 (0.75 to 5.35) 2.04 (0.76 to 5.46) 0.10 0.14
Yes (n=318) 1.0 (reference) 0.85 (0.39 to 1.89) 1.38 (0.65 to 2.94) 0.89 (0.39 to 2.03) 0.99
b-blockers
No (n=249) 1.0 (reference) 2.95 (1.16 to 7.50) 2.62 (1.0 to 6.88) 3.11 (1.17 to 8.26) 0.07 0.09
Yes (n=301) 1.0 (reference) 0.79 (0.36 to 1.77) 0.91 (0.41 to 2.04) 0.81 (0.35 to 1.88) 0.70
Ejection fraction, %
<60 (n=261) 1.0 (reference) 0.91 (0.37 to 2.21) 2.0 (0.85 to 4.66) 1.34 (0.56 to 3.23) 0.30 0.67
≥60 (n=289) 1.0 (reference) 1.01 (0.43 to 2.35) 1.21 (0.51 to 2.87) 1.31 (0.54 to 3.15) 0.48
Continued
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